Literature DB >> 25555909

Contributions of ionic interactions and protein dynamics to cytochrome P450 2D6 (CYP2D6) substrate and inhibitor binding.

An Wang1, C David Stout2, Qinghai Zhang2, Eric F Johnson3.   

Abstract

P450 2D6 contributes significantly to the metabolism of >15% of the 200 most marketed drugs. Open and closed crystal structures of P450 2D6 thioridazine complexes were obtained using different crystallization conditions. The protonated piperidine moiety of thioridazine forms a charge-stabilized hydrogen bond with Asp-301 in the active sites of both complexes. The more open conformation exhibits a second molecule of thioridazine bound in an expanded substrate access channel antechamber with its piperidine moiety forming a charge-stabilized hydrogen bond with Glu-222. Incubation of the crystalline open thioridazine complex with alternative ligands, prinomastat, quinidine, quinine, or ajmalicine, displaced both thioridazines. Quinine and ajmalicine formed charge-stabilized hydrogen bonds with Glu-216, whereas the protonated nitrogen of quinidine is equidistant from Asp-301 and Glu-216 with protonated nitrogen H-bonded to a water molecule in the access channel. Prinomastat is not ionized. Adaptations of active site side-chain rotamers and polypeptide conformations were evident between the complexes, with the binding of ajmalicine eliciting a closure of the open structure reflecting in part the inward movement of Glu-216 to form a hydrogen bond with ajmalicine as well as sparse lattice restraints that would hinder adaptations. These results indicate that P450 2D6 exhibits sufficient elasticity within the crystal lattice to allow the passage of compounds between the active site and bulk solvent and to adopt a more closed form that adapts for binding alternative ligands with different degrees of closure. These crystals provide a means to characterize substrate and inhibitor binding to the enzyme after replacement of thioridazine with alternative compounds.
© 2015 by The American Society for Biochemistry and Molecular Biology, Inc.

Entities:  

Keywords:  Ajmalicine; Crystal Structure; Cytochrome P450; Cytochrome P450 2D6 (CYP2D6); Drug Metabolism; Enzyme Inhibitor; Protein Structure; Quinidine; Quinine; Thioridazine

Mesh:

Substances:

Year:  2015        PMID: 25555909      PMCID: PMC4335244          DOI: 10.1074/jbc.M114.627661

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  41 in total

1.  Novel approach to predicting P450-mediated drug metabolism: development of a combined protein and pharmacophore model for CYP2D6.

Authors:  M J de Groot; M J Ackland; V A Horne; A A Alex; B C Jones
Journal:  J Med Chem       Date:  1999-05-06       Impact factor: 7.446

2.  THE CARBON MONOXIDE-BINDING PIGMENT OF LIVER MICROSOMES. II. SOLUBILIZATION, PURIFICATION, AND PROPERTIES.

Authors:  T OMURA; R SATO
Journal:  J Biol Chem       Date:  1964-07       Impact factor: 5.157

3.  PRODRG: a tool for high-throughput crystallography of protein-ligand complexes.

Authors:  Alexander W Schüttelkopf; Daan M F van Aalten
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2004-07-21

4.  Crystal structure of human cytochrome P450 2D6 with prinomastat bound.

Authors:  An Wang; Uzen Savas; Mei-Hui Hsu; C David Stout; Eric F Johnson
Journal:  J Biol Chem       Date:  2012-02-03       Impact factor: 5.157

5.  Structure of microsomal cytochrome P450 2B4 complexed with the antifungal drug bifonazole: insight into P450 conformational plasticity and membrane interaction.

Authors:  Yonghong Zhao; Mark A White; B K Muralidhara; Ling Sun; James R Halpert; C David Stout
Journal:  J Biol Chem       Date:  2005-12-21       Impact factor: 5.157

6.  Version 1.2 of the Crystallography and NMR system.

Authors:  Axel T Brunger
Journal:  Nat Protoc       Date:  2007       Impact factor: 13.491

7.  Xenobiotic and endobiotic inhibitors of cytochrome P-450dbl function, the target of the debrisoquine/sparteine type polymorphism.

Authors:  R Fonne-Pfister; U A Meyer
Journal:  Biochem Pharmacol       Date:  1988-10-15       Impact factor: 5.858

8.  Greater potency of mesoridazine and sulforidazine compared with the parent compound, thioridazine, on striatal dopamine autoreceptors.

Authors:  D M Niedzwiecki; R B Mailman; L X Cubeddu
Journal:  J Pharmacol Exp Ther       Date:  1984-03       Impact factor: 4.030

9.  Features and development of Coot.

Authors:  P Emsley; B Lohkamp; W G Scott; K Cowtan
Journal:  Acta Crystallogr D Biol Crystallogr       Date:  2010-03-24

10.  MOLE 2.0: advanced approach for analysis of biomacromolecular channels.

Authors:  David Sehnal; Radka Svobodová Vařeková; Karel Berka; Lukáš Pravda; Veronika Navrátilová; Pavel Banáš; Crina-Maria Ionescu; Michal Otyepka; Jaroslav Koča
Journal:  J Cheminform       Date:  2013-08-16       Impact factor: 5.514

View more
  26 in total

1.  Utilizing structures of CYP2D6 and BACE1 complexes to reduce risk of drug-drug interactions with a novel series of centrally efficacious BACE1 inhibitors.

Authors:  Michael A Brodney; Elizabeth M Beck; Christopher R Butler; Gabriela Barreiro; Eric F Johnson; David Riddell; Kevin Parris; Charles E Nolan; Ying Fan; Kevin Atchison; Cathleen Gonzales; Ashley E Robshaw; Shawn D Doran; Mark W Bundesmann; Leanne Buzon; Jason Dutra; Kevin Henegar; Erik LaChapelle; Xinjun Hou; Bruce N Rogers; Jayvardhan Pandit; Ricardo Lira; Luis Martinez-Alsina; Peter Mikochik; John C Murray; Kevin Ogilvie; Loren Price; Subas M Sakya; Aijia Yu; Yong Zhang; Brian T O'Neill
Journal:  J Med Chem       Date:  2015-04-01       Impact factor: 7.446

2.  Enzyme Kinetics of Oxidative Metabolism-Cytochromes P450.

Authors:  Ken Korzekwa
Journal:  Methods Mol Biol       Date:  2021

3.  Crystal Structures of Drug-Metabolizing CYPs.

Authors:  D Fernando Estrada; Amit Kumar; Christopher S Campomizzi; Natalie Jay
Journal:  Methods Mol Biol       Date:  2021

Review 4.  Cytochrome P450 2D6 and Parkinson's Disease: Polymorphism, Metabolic Role, Risk and Protection.

Authors:  Mohd Sami Ur Rasheed; Abhishek Kumar Mishra; Mahendra Pratap Singh
Journal:  Neurochem Res       Date:  2017-09-04       Impact factor: 3.996

5.  Solution Conformations and Dynamics of Substrate-Bound Cytochrome P450 MycG.

Authors:  Drew R Tietz; Larissa M Podust; David H Sherman; Thomas C Pochapsky
Journal:  Biochemistry       Date:  2017-05-16       Impact factor: 3.162

6.  NADH reduction of nitroaromatics as a probe for residual ferric form high-spin in a cytochrome P450.

Authors:  Thomas C Pochapsky; Nathan Wong; Yihao Zhuang; Jeffrey Futcher; Maria-Eirini Pandelia; Drew R Teitz; Allison M Colthart
Journal:  Biochim Biophys Acta Proteins Proteom       Date:  2017-05-01       Impact factor: 3.036

7.  Conformational selection dominates binding of steroids to human cytochrome P450 17A1.

Authors:  F Peter Guengerich; Clayton J Wilkey; Sarah M Glass; Michael J Reddish
Journal:  J Biol Chem       Date:  2019-05-09       Impact factor: 5.157

8.  Structural insights into xenobiotic and inhibitor binding to human aldehyde oxidase.

Authors:  Catarina Coelho; Alessandro Foti; Tobias Hartmann; Teresa Santos-Silva; Silke Leimkühler; Maria João Romão
Journal:  Nat Chem Biol       Date:  2015-08-31       Impact factor: 15.040

Review 9.  Recent Structural Insights into Cytochrome P450 Function.

Authors:  F Peter Guengerich; Michael R Waterman; Martin Egli
Journal:  Trends Pharmacol Sci       Date:  2016-06-04       Impact factor: 14.819

10.  An investigation into possible interactions among four vascular epidermal growth factor receptor-tyrosine kinase inhibitors with gefitinib.

Authors:  Chenxiang Wang; Lili Ying; Mi Jin; Fangfang Zhang; Dawei Shi; Ying Dai; Ziye Zhou
Journal:  Cancer Chemother Pharmacol       Date:  2020-11-10       Impact factor: 3.333

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.